Leigh MacMillan Archive — Page 22 of 83

November 15, 2021

Who’s who in the respiratory landscape

A metatranscriptomics method developed by Vanderbilt researchers simultaneously characterizes viruses, microbiome and host response in nasal swabs, opening opportunities to explore molecular interactions directly in clinical samples.

Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.
November 11, 2021

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

Roy Zent, MBBCh, PhD, left, Fabian Bock, MD, PhD, and colleagues are studying the factors involved in the maintenance and integrity of the kidney collecting duct.
November 4, 2021

Harrison Society researcher discovers key regulator of kidney cell structure

New research from Vanderbilt could aid efforts to promote kidney regeneration after injury or to develop engineered organs.

November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

November 1, 2021

Breast cancer survivors: eat nuts

Breast cancer survivors who reported eating nuts regularly had 50% reduced risk of breast cancer recurrence, metastasis or mortality, Vanderbilt epidemiologists found in Shanghai Breast Cancer Survival Study.

October 28, 2021

Pancreatic beta-cell booster

Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications.